



Market Announcement

28 November 2019

Sienna Cancer Diagnostics Limited (ASX: SDX) – Suspension from Official Quotation

Description

The securities of Sienna Cancer Diagnostics Limited ('SDX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of SDX, pending the release of an announcement regarding a capital raising.

Issued by

Cheng Tang

Senior Adviser, Listings Compliance (Melbourne)

28 November 2019

By email: Cheng.Tang@asx.com.au

Cheng Tang
Adviser, Listings Compliance (Melbourne)
ASX Limited

Dear Cheng

Request for voluntary suspension

Pursuant to Listing Rule 17.2, Sienna Cancer Diagnostics Limited ACN 099 803 460 (ASX:SDX) (the **Company**), requests a voluntary suspension be applied to the Company's securities.

Further to the Company's request for a trading halt on Tuesday, 26 November 2019, the Company is not in a position to make an announcement at this time, and requests a voluntary suspension, pending an announcement on the proposed capital raising referenced in the Company's trading halt request.

The Company requests that the suspension remain in place until the release of an announcement regarding this capital raising, which is expected to be Friday, 29 November 2019.

The Company confirms that it is not aware of any reason why this voluntary suspension should not be granted.

Please contact me should you have any questions.

Yours faithfully



Tony Di Pietro
Company Secretary
Sienna Cancer Diagnostics Limited